Joseph Kvedar is a Dermatology physician affiliated with Harvard University. OpenAlex indexes 283 publications with 11,157 citations (h-index 50); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
50 Staniford St
Suite 200
Boston, MA 021142517
Telephone
617-726-2914Registry record last updated 8 Jul 2007.
Clinical trials
- The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence
Sponsor: Massachusetts General Hospital
- Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program
Sponsor: Massachusetts General Hospital
- The Development and Evaluation of an "E-Visit" Program for the Management of Acne
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year20251 payment
- Amgen Inc.Program year20252 payments
- F. Hoffmann-La Roche AGProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
35.1%Corticosteroid23.7%Triamcinolone Acetonide79%Halobetasol Propionate13%Fluocinolone Acetonide8%Part D<11 patientsInterleukin-4 Receptor alpha Antagonist5.6%Dupixent Pen55%Dupixent Syringe45%Part D<11 patients+ 3 more classes in this area
Anti-infectives
27.6%Azole Antifungal16.6%Ketoconazole100%Part D≥47 patientsNitroimidazole Antimicrobial5.2%Metronidazole100%Part D≥18 patients+ 2 more classes in this area
Sensory organs
11.9%Corticosteroid11.9%Betamethasone Dipropionate53%Clobetasol Propionate28%Hydrocortisone20%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1988–1992 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”